psma car-t cell
Cell therapyexperimental
Clinical trial activity
5 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 8, 2019 (NCT04053062)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Carcinoma · Phase 1
- Carcinoma, Acinar Cell · Phase 1
- Carcinoma, Adenoid Cystic · Phase 1
- Carcinoma, Mucoepidermoid · Phase 1
- Genital Neoplasms, Male · Phase 1
- Neoplasms · Phase 1
- Neoplasms by Histologic Type · Phase 1
- Neoplasms by Site · Phase 1
- Prostatic Diseases · Phase 1
- Prostatic Neoplasms · Phase 1
- Prostatic Neoplasms, Castration-Resistant · Phase 1/Phase 2
- Salivary Gland Neoplasms · Phase 1
- Urogenital Neoplasms · Phase 1
Mechanism of action
- Glutamate carboxypeptidase IIImmunity, passive
FOLH1 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07240857 | Early Phase 1 (Phase 1) | Dec 31, 2025 | Zhejiang University |
| NCT06228404 | Early Phase 1 (Phase 1) | Mar 3, 2024 | Second Military Medical University, Shanghai Bioray Laboratory Inc. |
| NCT05656573 | Phase 1 | Jan 1, 2023 | People's Liberation Army of China |
| NCT04249947 | Phase 1 | Mar 31, 2020 | Poseida Therapeutics, Inc. |
| NCT04053062 | Phase 1/Phase 2 (Phase 2) | Aug 8, 2019 | Changhai Hospital, Shanghai Bioray Laboratory Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai Bioray Laboratory Inc. | For profit | 2 | 1 | 2 | 2019 |
| Changhai Hospital | Academic/Hospital | 1 | 0 | 1 | 2019 |
| People's Liberation Army of China | Government | 1 | 0 | 1 | 2023 |
| Poseida Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2020 |
| Second Military Medical University | Government | 1 | 1 | 1 | 2024 |
| Zhejiang University | Academic/Hospital | 1 | 1 | 1 | 2025 |
6 organizations
Page 1 / 1